Investor Relations

News Releases

Webcast
Apadaz Update Call
Friday, February 23, 2018 at 2:30 PM EST
Date Title
10/18/16
Summary ToggleKemPharm Announces Licensing Agreement with Acura Pharmaceuticals for Aversion® Abuse-Deterrent Technology Agreement focused on KemPharm's current and in-development IR Opioid Pipeline CORALVILLE, Iowa and PALATINE, Ill. , Oct. 18, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, and
10/11/16
Summary ToggleKemPharm Receives Clearance from FDA to Initiate Clinical Program for KP415, an Investigational Prodrug of D-Threo-Methylphenidate for the Treatment of ADHD KP415, KemPharm’s co-lead product candidate, is designed to be a predictably-dosed, extended release methylphenidate product CORALVILLE, Iowa , Oct. 11, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development
09/19/16
Summary ToggleKemPharm Files IND for KP415 for the Treatment of ADHD, An Investigational Prodrug of D-Threo-Methylphenidate KP415 is designed to be a predictably-dosed, extended release methylphenidate product CORALVILLE, Iowa , Sept. 19, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today
09/15/16
Summary ToggleKemPharm, Inc. Provides Corporate and Clinical Update Conference Call and Live Audio Webcast Scheduled for Today at 8:30 a.m. ET KemPharm adjusts product development timelines following full pipeline analysis and positions KP415 and KP201/IR as lead product candidates to capitalize on favorable developmental, regulatory and market conditions Announces
09/08/16
Summary ToggleKemPharm to Present Data at PAINWeek 2016 Poster Presentations to Highlight Tamper and Intranasal Abuse Resistance Studies Involving KemPharm’s Prodrug of Hydrocodone CORALVILLE, Iowa , Sept. 08, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development
08/10/16
Summary ToggleKemPharm, Inc. Reports Second Quarter 2016 Results Conference Call and Live Audio Webcast Scheduled for Today at 8:30 a.m. ET Recent Clinical Development & Regulatory Highlights : Completed FDA End of Review meeting for Apadaz™ following receipt of Complete Response Letter Reported results from KP511 Phase 1 Proof-of-Concept Trial; Announces
08/02/16
Summary ToggleKemPharm, Inc. to Report Second Quarter 2016 Results Conference Call and Live Audio Webcast Scheduled for August 10, 2016, 8:30 a.m. ET CORALVILLE, Iowa , Aug. 02, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced
07/28/16
Summary ToggleKemPharm to Present at Canaccord Genuity 36th Annual Growth Conference CORALVILLE, Iowa , July 28, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that its president and chief executive officer, Travis C.
07/14/16
Summary ToggleKemPharm Completes Key Regulatory Meetings with FDA for KP201/IR and KP415 KemPharm expects to file INDs for both product candidates during second half of 2016 CORALVILLE, Iowa , July 14, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs,  today
06/28/16
Summary ToggleKemPharm’s Prodrug of Hydromorphone, KP511, Demonstrates Comparable Oral Pharmacokinetics to Hydromorphone in Phase 1 Trial KP511 clinical data consistent with preclinical animal data CORALVILLE, Iowa , June 28, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced results from a Phase 1
06/13/16
Summary ToggleFDA Issues Complete Response Letter for Apadaz™ New Drug Application CORALVILLE, Iowa , June 13, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the U.S. Food and Drug Administration ( FDA ) has issued a Complete Response
06/09/16
Summary ToggleKemPharm Files NDA Amendment Request with FDA for Apadaz™ Discussions On-going with FDA on Potential Apadaz Product Labeling CORALVILLE, Iowa , June 09, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that it has filed
06/06/16
Summary ToggleKemPharm to Present Data from Pharmacokinetic Trial for Investigational Prodrug Benzhydrocodone at the 2016 International Conference on Opioids CORALVILLE, Iowa , June 06, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that it will present data from a study (KP201.A03) evaluating the pharmacokinetics
05/18/16
Summary ToggleKemPharm, Inc. to Host Annual Meeting of Stockholders on Tuesday, May 24, 2016 at 9:00 a.m. ET CORALVILLE, Iowa , May 18, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that KemPharm will host its annual meeting of stockholders on Tuesday, May 24, 2016 ,
05/12/16
Summary ToggleKemPharm, Inc. Reports First Quarter 2016 Results Conference Call and Live Audio Webcast Scheduled for Today at 4:30 p.m. ET Recent Clinical Development & Regulatory Highlights : Introduced Apadaz™ as the proprietary name for KP201/APAP FDA Advisory Committees voted 16 to 4 in support of Apadaz approval; voted 18 to 2 against inclusion of
05/10/16
Summary ToggleKemPharm Receives “Fast Track” Designation for KP511, an Investigational Prodrug of Hydromorphone KemPharm developing KP511 as an abuse-deterrent, extended-release product candidate – KP511/ER CORALVILLE, Iowa , May 10, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today
05/05/16
Summary ToggleStatement Regarding FDA Advisory Committee Meeting on KemPharm’s Abuse-Deterrent Product Candidate Apadaz™ CORALVILLE, Iowa , May 05, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced that the Anesthetic and Analgesic Drug Products Advisory Committee and the Drug
05/05/16
Summary ToggleFDA Advisory Committees To Review KemPharm’s Abuse-Deterrent Drug Candidate Apadaz™ Trading of KMPH Common Stock Halted KemPharm Conference Call Today at 6:15 p.m. ET CORALVILLE, Iowa , May 05, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, today announced
05/03/16
Summary ToggleKemPharm, Inc. to Report First Quarter 2016 Results Conference Call and Live Audio Webcast Scheduled for May 12, 2016, 4:30 p.m. ET CORALVILLE, Iowa , May 03, 2016 (GLOBE NEWSWIRE) -- KemPharm, Inc. (NASDAQ:KMPH), a clinical-stage specialty pharmaceutical company engaged in the discovery and development of proprietary prodrugs, announced today that
04/19/16
Summary ToggleKemPharm Announces New Additions to Senior Leadership Team Daniel L. Cohen , global public policy and government relations leader, appointed Executive Vice President, Government and Public Relations Rene A. Braeckman , Ph.D., clinical development expert, appointed Vice President, Clinical Development CORALVILLE, Iowa , April 19, 2016 (GLOBE NEWSWIRE) --